Open AccessSafety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
Author(s) -
Matthias Griese,
Stéfano Costa,
Rachel W. Linnemann,
Marcus Mall,
Edward F. McKone,
Deepika Polineni,
Bradley S. Quon,
Felix C. Ringshausen,
Jennifer L. TaylorCousar,
Nicholas Withers,
Samuel M. Moskowitz,
Cori Daines
Publication year - 2021
Publication title -
american journal of respiratory and critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.272
H-Index - 374
eISSN - 1535-4970
pISSN - 1073-449X
DOI - 10.1164/rccm.202008-3176le
Subject(s) - ivacaftor , medicine , cystic fibrosis , interim , open label , interim analysis , clinical trial , cystic fibrosis transmembrane conductance regulator , archaeology , history